TNFRSF4 and breast carcinoma: For example, combination therapy using the protein ligand of OX40, OX40L, fused to a cancer vaccine have been shown to reduce breast cancer metastasis, by enhancing antigen specific CD4+ and CD8+ T cell responses and inhibiting immunosuppressive Treg responses (Malamas et al., 2017).